Clinical meaning
Mood stabilizers target the neurobiological underpinnings of bipolar disorder, a condition characterized by dysregulated neuronal excitability, disrupted circadian rhythms, and altered intracellular signaling cascades. Lithium, the prototype mood stabilizer, exerts therapeutic effects through multiple intracellular mechanisms: it inhibits inositol monophosphatase (IMPase), depleting the phosphatidylinositol signaling pathway and dampening excessive neuronal signaling; it inhibits glycogen synthase kinase-3 beta (GSK-3β), a kinase involved in neuronal apoptosis, circadian rhythm regulation, and neurotransmitter release; and it upregulates neuroprotective factors including brain-derived neurotrophic factor (BDNF) and Bcl-2 anti-apoptotic protein. Lithium is a monovalent cation handled by the kidneys similarly to sodium; it is freely filtered at the glomerulus and 80% is reabsorbed in the proximal tubule via sodium-lithium countertransport, making its serum level exquisitely sensitive to sodium balance, hydration status, and drugs affecting renal sodium handling (thiazides, NSAIDs, ACE inhibitors all increase lithium levels). Valproic acid (valproate) enhances GABAergic neurotransmission by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase (increasing synaptic GABA concentrations), blocks voltage-gated sodium channels (reducing neuronal firing), and modulates intracellular signaling through histone deacetylase (HDAC) inhibition affecting gene expression. Carbamazepine and its derivative...